Background: Flow diversion with the Pipeline embolization device (PED) is an effective neuro-endovascular method and increasingly accepted for the treatment of cerebral aneurysms. Acute in situ thrombosis is a known complication of PED procedures. There is limited experience in the flow diversion literature on the use of abciximab (ReoPro) for the management of acute thrombus formation in PED cases. Methods: Data were collected retrospectively on patients who received intra-arterial (IA) ReoPro with or without subsequent intravenous (IV) infusion during PED flow diversion treatment of intracranial aneurysms. Results: A total of 30 cases in patients with a mean age of 56.7 years (range 36–84) and a mean aneurysm size of 8.6 mm (range 2–25) were identified to have intraprocedural thromboembolic complications during PED treatment. IA ReoPro was administered in all cases, with 20 cases receiving increments of 5-mg boluses and 10 cases receiving a 0.125 mg/kg IA bolus (half cardiac dosing). Complete or partial recanalization was achieved in 100% of the cases. IV ReoPro infusion at 0.125 μg/kg/min for 12 h was administered postprocedurally in 22 cases with a residual thrombus. Postprocedurally, 18 patients were transitioned from clopidogrel (Plavix) to prasugrel (Effient). The majority of the cases (23/30; 77%) were discharged home. Periprocedural intracranial hemorrhage was noted in 2 cases (7%) and radiographic infarct was noted in 4 cases (13%), with an overall mortality of 0% at the time of initial discharge. Clinical follow-up was available for 28/30 patients. The average duration of follow-up was 11.7 months, at which time 23/28 (82%) of the patients had a modified Rankin Scale score of 0. Conclusions: IA ReoPro administration is an effective and safe rescue strategy for the management of acute intraprocedural thromboembolic complications during PED treatment. Using a dosing strategy of either 5-mg increments or a 0.125 mg/kg IA bolus (half cardiac dosing) can provide high rates of recanalization with low rates of hemorrhagic complications and long-term morbidity.

Keywords:
Abciximab, Aneurysm, Endovascular treatment, Flow diversion, Pipeline embolization device, Thrombosis
1.
Kallmes DF, Hanel R, Lopes D, Boccardi E, Bonafé A, Cekirge S, Fiorella D, Jabbour P, Levy E, McDougall C, Siddiqui A, Szikora I, Woo H, Albuquerque F, Bozorgchami H, Dashti SR, Delgado Almandoz JE, Kelly ME, Turner R 4th, Woodward BK, Brinjikji W, Lanzino G, Lylyk P: International retrospective study of the Pipeline Embolization Device: a multicenter aneurysm treatment study. AJNR Am J Neuroradiol 2015; 36: 108–115.
2.
Becske T, Brinjikji W, Potts MB, Kallmes DF, Shapiro M, Moran CJ, Levy EI, McDougall CG, Szikora I, Lanzino G, Woo HH, Lopes DK, Siddiqui AH, Albuquerque FC, Fiorella DJ, Saatci I, Cekirge SH, Berez AL, Cher DJ, Berentei Z, Marosfoi M, Nelson PK: Long-term clinical and angiographic outcomes following Pipeline Embolization Device treatment of complex internal carotid artery aneurysms: five-year results of the Pipeline for Uncoilable or Failed Aneurysms trial. Neurosurgery 2017; 80: 40–48.
3.
Jiang B, Paff M, Colby GP, Coon AL, Lin LM: Cerebral aneurysm treatment: modern neurovascular techniques. Stroke Vasc Neurol 2016; 1: 93–100.
4.
Colby GP, Lin LM, Gomez JF, Paul AR, Huang J, Tamargo RJ, Coon AL: Immediate procedural outcomes in 35 consecutive Pipeline embolization cases: a single-center, single-user experience. J Neurointerv Surg 2013; 5: 237–246.
5.
Colby GP, Lin LM, Caplan JM, Jiang B, Huang J, Tamargo RJ, Coon AL: Immediate procedural outcomes in 44 consecutive Pipeline Flex cases: the first North American single-center series. J Neurointerv Surg 2016; 8: 702–709.
6.
Lin LM, Colby GP, Kim JE, Huang J, Tamargo RJ, Coon AL: Immediate and follow-up results for 44 consecutive cases of small (< 10 mm) internal carotid artery aneurysms treated with the Pipeline embolization device. Surg Neurol Int 2013; 4: 114.
7.
Saatci I, Yavuz K, Ozer C, Geyik S, Cekirge HS: Treatment of intracranial aneurysms using the Pipeline flow-diverter embolization device: a single-center experience with long-term follow-up results. AJNR Am J Neuroradiol 2012; 33: 1436–1446.
8.
Bender MT, Lin LM, Colby GP, Lubelski D, Huang J, Tamargo RJ, Coon AL: P2Y12 hyporesponse (PRU > 200) is not associated with increased thromboembolic complications in anterior circulation Pipeline. J Neurointerv Surg 2017; 9: 978–981.
9.
Brinjikji W, Murad MH, Lanzino G, Cloft HJ, Kallmes DF: Endovascular treatment of intracranial aneurysms with flow diverters: a meta-analysis. Stroke 2013; 44: 442–447.
10.
Patel A, Miller TR, Shivashankar R, Jindal G, Gandhi D: Early angiographic signs of acute thrombus formation following cerebral aneurysm treatment with the Pipeline embolization device. J Neurointerv Surg 2017; 9: 1125–1130.
11.
Skukalek SL, Winkler AM, Kang J, Dion JE, Cawley CM, Webb A, Dannenbaum MJ, Schuette AJ, Asbury B, Tong FC: Effect of antiplatelet therapy and platelet function testing on hemorrhagic and thrombotic complications in patients with cerebral aneurysms treated with the Pipeline embolization device: a review and meta-analysis. J Neurointerv Surg 2016; 8: 58–65.
12.
Park JH, Kim JE, Sheen SH, Jung CK, Kwon BJ, Kwon OK, Oh CW, Han MH, Han DH: Intraarterial abciximab for treatment of thromboembolism during coil embolization of intracranial aneurysms: outcome and fatal hemorrhagic complications. J Neurosurg 2008; 108: 450–457.
13.
Ries T, Siemonsen S, Grzyska U, Zeumer H, Fiehler J: Abciximab is a safe rescue therapy in thromboembolic events complicating cerebral aneurysm coil embolization: single center experience in 42 cases and review of the literature. Stroke 2009; 40: 1750–1757.
14.
Velat GJ, Burry MV, Eskioglu E, Dettorre RR, Firment CS, Mericle RA: The use of abciximab in the treatment of acute cerebral thromboembolic events during neuroendovascular procedures. Surg Neurol 2006; 65: 352–358, discussion 358–359.
15.
Lall RR, Crobeddu E, Lanzino G, Cloft HJ, Kallmes DF: Acute branch occlusion after Pipeline embolization of intracranial aneurysms. J Clin Neurosci 2014; 21: 668–672.
16.
Colby GP, Lin LM, Huang J, Tamargo RJ, Coon AL: Utilization of the Navien distal intracranial catheter in 78 cases of anterior circulation aneurysm treatment with the Pipeline embolization device. J Neurointerv Surg 2013; 5(suppl 3):iii16–iii21.
17.
Lin LM, Colby GP, Jiang B, Uwandu C, Huang J, Tamargo RJ, Coon AL: Classification of cavernous internal carotid artery tortuosity: a predictor of procedural complexity in Pipeline embolization. J Neurointerv Surg 2015; 7: 628–633.
18.
Yang H, Li Y, Jiang Y: Insufficient platelet inhibition and thromboembolic complications in patients with intracranial aneurysms after stent placement. J Neurosurg 2016; 125: 247–253.
19.
Adeeb N, Griessenauer CJ, Moore JM, Foreman PM, Shallwani H, Motiei-Langroudi R, Gupta R, Baccin CE, Alturki A, Harrigan MR, Siddiqui AH, Levy EI, Ogilvy CS, Thomas AJ: Ischemic stroke after treatment of intraprocedural thrombosis during stent-assisted coiling and flow diversion. Stroke 2017; 48: 1098–1100.
20.
Adeeb N, Griessenauer CJ, Foreman PM, Moore JM, Shallwani H, Motiei-Langroudi R, Alturki A, Siddiqui AH, Levy EI, Harrigan MR, Ogilvy CS, Thomas AJ: Use of platelet function testing before Pipeline embolization device placement: a multicenter cohort study. Stroke 2017; 48: 1322–1330.
21.
EPIC Investigators: Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. N Engl J Med 1994; 330: 956–961.
22.
EPIC Investigators: Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. N Engl J Med 1997; 336: 1689–1696.
23.
Fiorella D, Albuquerque FC, Han P, McDougall CG: Strategies for the management of intraprocedural thromboembolic complications with abciximab (ReoPro). Neurosurgery 2004; 54: 1089–1097; discussion 1097–1098.
24.
Mounayer C, Piotin M, Baldi S, Spelle L, Moret J: Intraarterial administration of abciximab for thromboembolic events occurring during aneurysm coil placement. AJNR Am J Neuroradiol 2003; 24: 2039–2043.
25.
Alexander MJ, Duckwiler GR, Gobin YP, Viñuela F: Management of intraprocedural arterial thrombus in cerebral aneurysm embolization with abciximab: technical case report. Neurosurgery 2002; 50: 899–901; discussion 901–902.
26.
Aggour M, Pierot L, Kadziolka K, Gomis P, Graftieaux JP: Abciximab treatment modalities for thromboembolic events related to aneurysm coiling. Neurosurgery 2010; 67(suppl Operative): 503–508.
27.
Bendok BR, Padalino DJ, Levy EI, Qureshi AI, Guterman LR, Hopkins LN: Intravenous abciximab for parent vessel thrombus during basilar apex aneurysm coil embolization: case report and literature review. Surg Neurol 2004; 62: 304–311.
28.
Dornbos D 3rd, Katz JS, Youssef P, Powers CJ, Nimjee SM: Glycoprotein IIb/IIIa inhibitors in prevention and rescue treatment of thromboembolic complications during endovascular embolization of intracranial aneurysms. Neurosurgery 2017, Epub ahead of print.
29.
Brinjikji W, Morales-Valero SF, Murad MH, Cloft HJ, Kallmes DF: Rescue treatment of thromboembolic complications during endovascular treatment of cerebral aneurysms: a meta-analysis. AJNR Am J Neuroradiol 2015; 36: 121–125.
30.
Walsh RD, Barrett KM, Aguilar MI, Lanzino G, Hanel RA, Miller DA, Chong BW, Freeman WD: Intracranial hemorrhage following neuroendovascular procedures with abciximab is associated with high mortality: a multicenter series. Neurocrit Care 2011; 15: 85–95.
31.
Ramakrishnan P, Yoo AJ, Rabinov JD, Ogilvy CS, Hirsch JA, Nogueira RG: Intra-arterial eptifibatide in the management of thromboembolism during endovascular treatment of intracranial aneurysms: case series and a review of the literature. Interv Neurol 2013; 2: 19–29.
32.
Sedat J, Chau Y, Mondot L, Chemla R, Lonjon M, Padovani B: Is eptifibatide a safe and effective rescue therapy in thromboembolic events complicating cerebral aneurysm coil embolization? Single-center experience in 42 cases and review of the literature. Neuroradiology 2014; 56: 145–153.
© 2018 S. Karger AG, Basel
2018
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.